The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification

Armen Sanosyan, Alexis Fayd’herbe de Maudave, Karine Bolloré, Valérie Zimmermann, Vincent Foulongne, Philippe Van de Perre, Edouard Tuaillon

To cite this version:

Armen Sanosyan, Alexis Fayd’herbe de Maudave, Karine Bolloré, Valérie Zimmermann, Vincent Foulongne, et al.. The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification. PLoS ONE, Public Library of Science, 2017, 12 (8), pp.e0183856. 10.1371/journal.pone.0183856 . hal-01890162

HAL Id: hal-01890162
https://hal.archives-ouvertes.fr/hal-01890162
Submitted on 9 Oct 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Distributed under a Creative Commons Attribution 4.0 International License
RESEARCH ARTICLE
The impact of targeting repetitive BamHI-W sequences on the sensitivity and precision of EBV DNA quantification

Armen Sanosyan1,2*, Alexis Fayd’herbe de Maudave2, Karine Bollore2, Valérie Zimmermann3, Vincent Foulongne1,2, Philippe Van de Perre1,2, Edouard Tuaillon1,2

1 CHU Montpellier, Montpellier, France, 2 Pathogenes is and Control of Chronic Infections, INSERM, EFS, Université de Montpellier, Montpellier, France, 3 Institut de Génétique Moléculaire de Montpellier, Centre National de la Recherche Scientifique, UMR 5535, Université de Montpellier, Montpellier, France

* armen.sanosyan@yahoo.com

Abstract

Background

Viral load monitoring and early Epstein-Barr virus (EBV) DNA detection are essential in routine laboratory testing, especially in preemptive management of Post-transplant Lymphoproliferative Disorder. Targeting the repetitive BamHI-W sequence was shown to increase the sensitivity of EBV DNA quantification, but the variability of BamHI-W reiterations was suggested to be a source of quantification bias. We aimed to assess the extent of variability associated with BamHI-W PCR and its impact on the sensitivity of EBV DNA quantification using the 1st WHO international standard, EBV strains and clinical samples.

Methods

Repetitive BamHI-W- and LMP2 single-sequences were amplified by in-house qPCRs and BXLF-1 sequence by a commercial assay (EBV R-gene™, BioMerieux). Linearity and limits of detection of in-house methods were assessed. The impact of repeated versus single target sequences on EBV DNA quantification precision was tested on B95.8 and Raji cell lines, possessing 11 and 7 copies of the BamHI-W sequence, respectively, and on clinical samples.

Results

BamHI-W qPCR demonstrated a lower limit of detection compared to LMP2 qPCR (2.33 \( \log_{10} \) versus 3.08 \( \log_{10} \) IU/mL; \( P = 0.0002 \)). BamHI-W qPCR underestimated the EBV DNA load on Raji strain which contained fewer BamHI-W copies than the WHO standard derived from the B95.8 EBV strain (mean bias: - 0.21 \( \log_{10} \); 95% CI, -0.54 to 0.12). Comparison of BamHI-W qPCR versus LMP2 and BXLF-1 qPCR showed an acceptable variability between EBV DNA levels in clinical samples with the mean bias being within 0.5 \( \log_{10} \) IU/mL EBV DNA, whereas a better quantitative concordance was observed between LMP2 and BXLF-1 assays.
Conclusions
Targeting BamHI-W resulted in a higher sensitivity compared to LMP2 but the variable reiterations of BamHI-W segment are associated with higher quantification variability. BamHI-W can be considered for clinical and therapeutic monitoring to detect an early EBV DNA and a dynamic change in viral load.

Introduction
 Epstein-Barr virus (EBV) is a member of gamma herpesviruses subfamily which infects more than 95% of adults [1]. Although generally asymptomatic EBV is responsible for Infectious Mononucleosis, an often self-limited disease of adolescents characterized with fever, lymphadenopathy, splenomegaly and atypical lymphocytes [2]. The importance of EBV rose in the modern era of immunosuppression with AIDS, transplants or cancer chemotherapy, where it was demonstrated that high EBV viral load is associated with the risk of lymphoproliferative disorders [3]. EBV DNA measurement in peripheral blood compartments became routine practice to help diagnose, monitor, prevent and treat the post-transplant lymphoproliferative disorder (PTLD) in immunocompromised recipients [4,5]. Although all three blood compartments: whole blood; Peripheral Blood Mononuclear Cells (PBMC) and plasma are appropriate specimens for EBV DNA monitoring, recent evidence suggests plasma to be more indicative for EBV-associated PTLD [5,6].

Sensitive and accurate detection of EBV DNA at the early stages of the PTLD remains crucial in the monitoring of transplanted patients [3,5,7]. Despite the existence of commercial kits, clinical laboratories continue to use in-house real-time PCR (qPCR) assays [4]. Additionally, World Health Organization (WHO) implemented the EBV DNA international standard that was produced from B95.8 EBV strain to standardize the assays and reduce the inter-laboratory variability by using international units (IU) [8]. The introduction of the “1st WHO International standard for Epstein—Barr virus for Nucleic Acid Amplification Technique” (NIBSC code: 09/260) aimed to provide the laboratories with a single reference source of defined EBV DNA [8].

One possible mean to increase the sensitivity of the qPCR assay is to target the repetitive sequences of the pathogen genome [9,10]. The assays amplifying BamHI-W (Bam-W) fragment, which is a tandem reiterated sequence found in the EBNA-LP (EBV nuclear antigen leader protein) region of EBV genome were shown to be more sensitive compared to a single sequence qPCRs [11,12]. Bam-W represents a highly conserved sequence that is reiterated in average 6 times per EBV isolate [13,14]. However, the reiteration of Bam-W region is inconstant, ranging from 5 to 11 copies in different isolates (Fig 1) [14,15]. Variability in Bam-W copy numbers may add an imprecision in EBV quantification due to the differences between the Bam-W sequence numbers in the quantification standards and tested samples [11]. Although the precision of the assay was questioned, studies continue to demonstrate the effectiveness and good quantitative agreement of Bam-W qPCR [16,17]. However, to the best of our knowledge no study has explored the extent of EBV DNA quantification imprecisions and the gain of the sensitivity determined by the variability of Bam-W reiterations.

In the current study we developed two in-house qPCR assays targeting the single and repetitive sequences of EBV genome and compared the results between in-house and commercial tests. The impact of targeting repetitive Bam-W sequence on the sensitivity and precision of EBV DNA quantification was evaluated across the wide range of EBV viral loads using EBV strains and clinical samples.
Material and methods

Sample preparation and quantitative standards

EBV strains from B95.8 and Raji cell lines (kindly donated by Prof. Claude Desgranges), were used in this study. B95.8 (GenBank: V01555.2) and Raji (GenBank: KF717093.1) complete genome sequences contain 11 and 7 Bam-W copy numbers, respectively. Supernatants from Raji and B95.8 EBV cell lines were harvested after three days of incubation without any stimulation, tested by the EBV R-gene™ kit (Biomerieux, Marcy l’Etoile, France) and serially diluted from 2.6 to 6.7 log_{10} IU/mL. Thirty six clinical samples of whole blood collected from patients visiting University Hospital Center of Montpellier were also included with 25 positives and 11 negatives for EBV DNA. All participants had provided verbal informed consent at the initial workup, and the University Hospital Center of Montpellier ethic committee approved the collection with the reference: DC-2015-2473 for this study (Comité de Protection des Personnes Sud Méditerranée III). The 1st WHO international standard for EBV was ordered from the National Institute for Biological Standards and Control (NIBSC, UK) and dilutions in EBV DNA-negative plasma from blood donor were used for limit of detection (LOD) assays and serial 10-fold dilutions ranging from 5 000 000 IU/mL (6.70 log_{10} IU/mL) to 500 IU/mL (2.70 log_{10} IU/mL) were used for estimation of the linear dynamic ranges of in-house tests.

DNA extraction

DNA from 200 μl of whole blood was extracted and eluted into a final volume of 60 μl using a QIAsymphony DNA Mini Kit on the QIAsymphony SP automated DNA extractor (Qiagen, Hilden, Germany).

EBV DNA from cell supernatants and 1st WHO International standard was extracted from 200 μl samples, eluted in 50 μl using the QIAamp DNA mini Kit (Qiagen) on the QIAcube automated DNA extractor (Qiagen).

EBV DNA quantification

Assays were performed using a LightCycler 480 instrument (Roche, Mannheim, Germany) in 96-well plate.

Fig 1. Schematic representation of linear form of EBV genome mapping the Bam-W reiterations and other targets of our study (shaded areas). TR–terminal repeats; LMP–latent membrane protein; letters represent BamHI degraded fragments of EBV genome.

https://doi.org/10.1371/journal.pone.0183856.g001
Three different targets were used to quantify EBV DNA in the study samples: a repetitive highly conserved Bam-W and a single LMP2 sequences for in-house qPCRs; and a BXLF-1 gene for the commercial EBV R-gene kit.

In-house qPCR reactions were performed in 20 μl final volume containing 5 μl of DNA and 5x DNA polymerase mix (Omunis, Clapiers, France) with the following thermocycling conditions: activation—95˚C for 12 minutes and amplification—95˚C for 15 seconds following 60˚C for 1 minute during 50 cycles. The sequences and concentrations of the primers and probes were:

**Bam-W qPCR** [18]— 400 nM of forward (AGTGGGCTTGTTTGTGACTCTC) and reverse (GG ACTCCTGGCGCTCTGTGAT) primers and 125 nM of TaqMan probe (6FAM-TTACGTAAGCCAGACACGACCCAATTGTGC−TAMRA).

**LMP2** [19]— 600 nM of forward (AGCTGTAACTGTGGTTTCCATG) and reverse (GCCCCCTGGCGAARAG) primers and 400 nM of probe (6FAM-CTGCTGCTACTGGCTTTCGTCCTCTGG−TAMRA).

Potential cross-reactivity with other viruses or genomic DNA was evaluated by BLAST sequence analysis.

The R-gene PCR targeting the BXLF-1 region of EBV genome was used according to the manufacturer’s recommendations. Analytical performances of R-gene EBV™ are: detection limit of 182 copies/mL on Namalwa cell dilutions (performed by the manufacturer); 500 copies/mL on a whole blood and the linearity ranging from 2.5×10² to 2.5×10⁶ copies/mL [20].

Quantification results for experimental samples were extrapolated based on the standard curve. All viral loads were expressed as IU/mL. All in-house assays and R-gene assay on cell lines were quantified based on calibration curves constructed by WHO EBV standard. EBV DNA loads of clinical samples were converted from copies/mL to IU/mL using the 0.44 conversion factor previously calculated in the clinical laboratory of virology of our institution regarding the workflow used for the EBV viral load determination by a method described elsewhere [21].

**PCR performances and statistics**

The linear dynamic ranges of the in-house assays were evaluated by plotting the results of 10-fold serial dilutions of the WHO standard ranging between 5×10² to 5×10⁶ IU/mL in three different runs with 8–13 replicates of each concentration. The linear regression analysis between assigned and observed values was used for linearity assessment. The median values, interquartile ranges of each concentration and regression coefficient were determined.

The capacity to amplify the lower concentrations of EBV DNA was explored by testing the LOD, which assumes the lowest EBV DNA load detected in 95% of the times. To determine the LOD, serial dilutions ranging from 80 to 1000 IU/mL were tested from 4 to 62 times in three different runs by each in-house assay. The loads that were estimated to have 95% of positivity were tested at least 8 times per run, whereas the loads having absolute positivity rate were tested at least 4 times in total. Lower LOD was expected using the Bam-W qPCR. The probit regression analysis with a value equal to 6.65 probability of units was used to determine the LOD for both in-house PCRs as described elsewhere [22]. Values having absolute positivity rate (100% tested positive) do not participate in probit analysis.

Bland-Altman bias plots were used to assess the differences between repeated (Bam-W) and single target qPCR assays (LMP2 and R-gene) on EBV strains and clinical samples. For each plot, mean bias and 95% confidence interval (95% CI) of the bias were calculated and the mean biases were compared using Student’s t-test. EBV strains containing different numbers of Bam-W sequences were used to evaluate the bias in EBV quantification due to a known
variation in reiteration of a repeated sequence. Confidence interval of bias was used to test the concordance between results from clinical samples using repeated- versus single-target qPCRs. Wider variations around the mean bias line would reflect variations in the ratio of Bam-W/single target (LMP2 or BXLF-1) in clinical samples. The agreement between the different qPCRs was analyzed using Cohen’s kappa test.

All statistical analyses were done with MS Excel and Graphpad Prism 6.0 (GraphPad Software, Inc., San Diego, CA). Graphpad Quickcalcs online software was used for Student’s t-test and kappa agreement.

Results

Analytical performances of Bam-W and LMP2 in-house qPCR assays

The Bam-W and LMP2 assays were linear between 500–500 000 IU/mL with regression coefficients of 0.99 (95% CI, 0.97–1.01) and 1.00 (95% CI, 0.98–1.02), respectively. The coefficient of determination ($R^2$) was 1.00 for Bam-W assay and 0.99 for LMP2 assay. Inter-quartile ranges were increasingly smaller from low to high concentrations in both tests, S1 Table (Fig 2).

A series of dilutions ranging from 1.9 to 3.0 $\log_{10}$ (80 to 1000) IU/mL were prepared by spiking the 1st WHO international standard in EBV DNA-negative plasma to evaluate the LOD of Bam-W and LMP2 qPCRs, S2 Table. LOD for Bam-W was set at 214 IU/mL (2.33 $\log_{10}$ IU/mL) and for LMP2 at 1215 IU/mL (3.08 $\log_{10}$ IU/mL); P = 0.0002 (Fig 3).

Impact of repeated versus single sequence PCR on EBV DNA quantification on B95.8 and Raji strains

The supernatants of B95.8 and Raji cell lines were tested with Bam-W and LMP2 in-house qPCRs and R-gene kit. Results were compared using Bland-Altman bias plots Table 1.
The difference in EBV DNA levels between LMP2 and R-gene assays were 0.15 log_{10} IU/mL (95% CI, -0.05 to 0.36) for Raji, and 0.07 log_{10} IU/mL (95% CI, -0.12 to 0.25) for B95.8 strain. The biases in EBV DNA in between the two cell lines were non-significant (P = 0.057) (Fig 4A). The differences between EBV DNA levels using in-house repeated target Bam-W qPCR versus R-gene qPCR were lower on Raji strain compared to B95.8 strain. The biases demonstrated on Bland-Altman plots showed higher EBV DNA levels on B95.8 strain using Bam-W qPCR compared to R-gene (bias, 0.15 log_{10} IU/mL; 95% CI, -0.20 to 0.51); whereas a negative bias was observed on Raji strain (bias, -0.05 log_{10} IU/mL; 95% CI, -0.24 to 0.13, P = 0.0049) (Fig 4B). Higher levels of discrepancies were observed in the lower concentrations of EBV.

Table 1. Biases, standard deviations and comparison of biases (P values) of Bland-Altman curves on different EBV strains.

|                    | B95.8 (Bias/SD) | Raji (Bias/SD) | P values |
|--------------------|-----------------|----------------|----------|
| LMP 2—R-gene       | 0.07/0.09       | 0.15/0.10      | 0.057    |
| Bam-W—R-gene       | 0.15/0.18       | -0.05/0.09     | 0.0049   |
| Bam-W—LMP2         | 0.09/0.12       | -0.21/0.17     | 0.0002   |

SD—standard deviation

https://doi.org/10.1371/journal.pone.0183856.t001
Comparison of Bam-W versus LMP2 (Fig 4C) demonstrated a clear separation between the EBV DNA of the two strains with biases equal to -0.21 log_{10} IU/mL (95% CI, -0.54 to 0.12) on Raji strain and 0.09 log_{10} IU/mL (95% CI, -0.15 to 0.33) on B95.8 strain (P = 0.0002).

Consequences of targeting repeated sequence on commutability of qPCR results

Testing whole blood extracts from clinical samples a good agreement of EBV DNA detection between commercial R-gene kit and in-house qPCRs was observed with following kappa values: 0.87 (95% CI, 0.69–1.00) for Bam-W and 0.66 (95% CI, 0.43–0.89) for LMP2 Table 2. EBV DNA load dispersion due to inconsistent copies of Bam-W was observed on the plots comparing Bam-W qPCR to LMP2 or R-gene qPCRs in clinical isolates (Fig 5). The distance between the bias confidence interval bands was from -0.30 to 0.01 for LMP2 versus R-gene (Fig 5A); from -0.18 to 0.80 log_{10} IU/mL for Bam-W versus R-gene (Fig 5B) and from -0.05 to 0.80 for Bam-W versus LMP2 (Fig 5C). However, all biases are within the acceptable ±0.5 log_{10} IU/mL range of difference.

Discussion

This study highlighted the impact of targeting Bam-W repetitive sequences on the sensitivity and quantification precision of EBV viral load. Targeting Bam-W region was shown to
increase the sensitivity but the variations in the reiteration number has long been suggested as a potential drawback especially in clinical settings [11,23].

The probit regression analyses on the plasma dilutions of WHO standard proved that the repeated Bam-W sequence qPCR had a LOD lower than LMP2 single repeat qPCR. Compared to LMP2, the gain of LOD targeting Bam-W was over 0.5 log\(_{10}\) IU/mL, which can be considered significant for qPCR method [21]. Based on the characteristics provided by the manufacturer, the LOD of the Bam-W PCR and R-gene EBV kit appeared comparable. In a study evaluating EBV PCR for diagnosing and monitoring PTLD Tsai et al. compared EBV plasma loads measured with 3 different qPCR methods (EBNA-1, LMP2 and EBER) and have shown that EBNA-1 had higher negative predictive value due to its higher sensitivity [24]. Further studies remain needed to evaluate the possible benefit of detection of low level of EBV DNA in plasma to predict disease progression or resolution of PTLD under therapy.

The bias in EBV DNA quantification related to variation in Bam-W repeat number was explored on Raji versus B95.8 strain. Theoretical underestimation on the Raji strain having 7 copies relative to the B95.8 strain having 11 copies can be calculated by logarithmic subtraction of the number of copies from the two cell lines (log\(_{10}\)7—log\(_{10}\)11 = -0.196 log\(_{10}\) IU/mL) which was close to the observed bias (-0.21 log\(_{10}\) IU/mL).

WHO standard made from B95.8 cell line contains 11 reiterations of Bam-W sequences and determines a possible quantification disagreement between the tested samples with variable Bam-W [16,25]. Our results confirmed this assumption, since the plots comparing the results of Bam-W qPCR with LMP2 or R-gene qPCRs in clinical samples made evident a visible dispersion of EBV DNA around the bias lines, whereas a narrower variation of bias confidence interval was observed on LMP2 versus R-gene plot. Abeynayake et al. have demonstrated commutable performances between in-house Bam-W qPCR and Artus (EBNA-1) commercial tests in clinical samples using WHO EBV standard. An acceptable difference of 0.5 log\(_{10}\) UI/mL was detected for around 90% of cases showing a good agreement between the two tests [16]. Testing serial dilutions (2.6–6.7 log\(_{10}\) IU/mL) of different cell lines we also obtained a difference between repetitive- and single-sequence qPCRs close to theoretic calculation that is within the acceptable 0.5 log\(_{10}\) IU/mL range [21]. In a study using plasmids containing 1 copy of each target for standard curve construction Le et al. compared three different qPCR assays (Bam-W; LMP2 and Polymerase 1). They demonstrated that although Bam-W overestimated the viral load in cell lines, in clinical samples all three can be interchangeably used for monitoring EBV DNA in nasopharyngeal carcinoma, however none of the authors described the limit of detection and sensitivity gain of the assays [15].

This suboptimal comparability of qPCR results may affect the interpretation when threshold is applied. The management of PTLD still lacks a common consensus around the EBV DNA threshold for preemptive therapy. Three EBV DNA thresholds of 1000, 10 000, 40 000 copies/mL have been suggested for Rituximab therapy [26–28].

| Table 2. Cohen’s kappa agreements of EBV DNA between qualitative results obtained from whole blood clinical sample of R-gene commercial kit and laboratory in-house Bam-W and LMP2 qPCR assays. |
|-----------------|-----------------|-----------------|-----------------|
|                 | R-gene positive samples (n = 25) | R-gene negative samples (n = 11) | Kappa agreement (95% CI) |
| Bam-W           |                  |                  |                  |
| positive        | 24               | 1                | 0.87 (0.69–1.00) |
| negative        | 1                | 10               |                  |
| LMP2            |                  |                  |                  |
| positive        | 19               | 0                | 0.66 (0.43–0.89) |
| negative        | 6                | 11               |                  |

https://doi.org/10.1371/journal.pone.0183856.t002
Using these thresholds in our clinical samples, we have detected 7 disagreements between Bam-W and R-gene tests and 2 between LMP2 and R-gene test. Hence, the repeated sequence qPCR yielded to higher sensitivity but also to higher variability oscillating around the bias line. Molecular assays targeting single sequence should be preferred for PTLD therapeutic management if a strict threshold is applied for EBV DNA monitoring. Although the introduction of WHO standard harmonized the assays by providing a common calibrator and reporting units, the lack of commonly accepted viral load threshold and specimen type for diagnosing EBV-related diseases still remain a substantial source of difficulties for interpretation of the results and for comparisons across laboratories.

In perspective, the interest of Bam-W qPCR may not only be confined in EBV DNA load monitoring but may also represent an additional source of information in the monitoring of EBV associated diseases. Ishii et al. demonstrated a significant correlation between Bam-W and LMP1 plasma qPCRs. However EBV DNA quantified by two methods did not exhibit the same dynamic change during the treatment of NK/T cell tumors [29].

EBNA-LP protein substantially contributes to EBV infected B cell oncogenic transformation [30,31]. The Bam-W reiteration number in EBNA-LP gene determines the size and thus

---

**Fig 5. Bland-Altman bias plots comparing Bam-W repeated- and LMP2 single-sequence qPCRs on whole blood extracts of clinical samples.** Values having EBV DNA load equal or higher than LOD of LMP2 (A) and Bam-W (B) in-house qPCR assays were compared with the initial clinical values (equal or higher than LOD) performed by EBV R-gene commercial kit, and with each other (C). Dotted lines represent the borders of 95% CI and 0 point.

https://doi.org/10.1371/journal.pone.0183856.g005
the functional ability of EBNA-LP [12]. By using recombinant EBV, Tierney et al. have shown that the optimal transformation capacity of EBNA LP is with 5 to 8 Bam-W repeats, while EBV virions with W reiterations under 5 copies significantly decreased their transformation ability [12].

In conclusion, in-house Bam-W repeated target qPCR is more sensitive than single repeat LMP2 qPCR with significantly lower limit of detection. Despite the quantification imprecisions imposed by the variable numbers of Bam-W reiteration an acceptable agreement exists between Bam-W and single target qPCR assays. Hence, Bam-W can be considered in further studies for the early detection of EBV DNA and for therapeutic monitoring based on EBV viral load dynamic changes.

**Supporting information**

**S1 Table.** Reportable range of two in-house EBV DNA quantification assays on serial dilutions of the 1st WHO international standard for EBV.

**(DOCX)**

**S2 Table.** Limit of detection using probit regression analysis.

**(DOCX)**

**S1 File.** Raw data PLOS ONE data 19.05.2017.

**(XLSX)**

**Acknowledgments**

The authors thank Prof. Claude Desgranges for kindly donating B95.8 and Raji cell lines; Cara-Chan Manville for reviewing the English language of this manuscript and Prof. Naomi Taylor for critically reviewing the manuscript.

**Author Contributions**

**Conceptualization:** Armen Sanosyan, Alexis Fay'd'herbe de Maudave, Edouard Tuaillon.

**Data curation:** Armen Sanosyan, Alexis Fay'd'herbe de Maudave, Karine Bollore, Edouard Tuaillon.

**Formal analysis:** Armen Sanosyan, Alexis Fay'd'herbe de Maudave.

**Funding acquisition:** Armen Sanosyan, Philippe Van de Perre, Edouard Tuaillon.

**Investigation:** Armen Sanosyan, Alexis Fay'd'herbe de Maudave, Karine Bollore, Vincent Foulongne.

**Methodology:** Armen Sanosyan, Valérie Zimmermann, Vincent Foulongne, Edouard Tuaillon.

**Project administration:** Philippe Van de Perre, Edouard Tuaillon.

**Resources:** Armen Sanosyan, Karine Bollore, Edouard Tuaillon.

**Software:** Armen Sanosyan.

**Supervision:** Valérie Zimmermann, Philippe Van de Perre, Edouard Tuaillon.

**Validation:** Vincent Foulongne, Philippe Van de Perre, Edouard Tuaillon.

**Visualization:** Armen Sanosyan, Edouard Tuaillon.

**Writing – original draft:** Armen Sanosyan, Alexis Fay'd'herbe de Maudave.
Writing – review & editing: Karine Bollore, Valérie Zimmermann, Vincent Foulongne, Philippe Van de Perre, Edouard Tuaillon.

References
1. Kieff E. and Rickinson A. B. “Epstein-Barr virus,” in Fields Virology, Knipe D. M. and Howley P. M., Eds., 4th edition. Lippincott Williams & Wilkins; Philadelphia; 2001.
2. Vouloumanou EK, Rafailidis PI, Falagas ME. Current diagnosis and management of infectious mononucleosis. Curr Opin Hematol. 2012; 19: 14–20. https://doi.org/10.1097/MOH.0b013e328334daa0 PMID: 22123662
3. Gulley ML, Tang W. Using Epstein-Barr Viral Load Assays To Diagnose, Monitor, and Prevent Post-transplant Lymphoproliferative Disorder. Clin Microbiol Rev. 2010; 23: 350–366. https://doi.org/10.1128/CMR.00006-09 PMID: 20375356
4. Gärtner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol. 2010; 48: 82–90. https://doi.org/10.1016/j.jcv.2010.03.016 PMID: 20395167
5. Styczynski J, van der Velden W, Fox CP, Engelhard D, de la Camara R, Cordonnier C, et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders. Haematologica. 2016; 101: 803–811. https://doi.org/10.3324/haematol.2016.144428 PMID: 27365460
6. Kanakry JA, Hegde AM, Durand CM, Massie AB, Greer AE, Ambinder RF, et al. The clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseases. Blood. 2016; 127: 2007–2017. https://doi.org/10.1182/blood-2015-09-672030 PMID: 26744460
7. Kamdar KY, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant. 2011; 16: 274–280. https://doi.org/10.1097/MOT.0b013e3283467515 PMID: 21467936
8. WHO | International reference materials. In: WHO [Internet]. [cited 14 Aug 2015]. Available: http://www.who.int/bloodproducts/ref_materials/en/
9. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-Sensitive Detection of Plasmodium falciparum by Amplification of Multi-Copy Subtelomeric Targets. PLOS Med. 2015; 12: e1001788. https://doi.org/10.1371/journal.pmed.1001788 PMID: 25734259
10. Edvinsson B, Lappalainen M, Evengård B. Real-time PCR targeting a 529-bp repeat element for diagnosis of toxoplasmosis. Clin Microbiol Infect. 2006; 12: 131–136. https://doi.org/10.1111/j.1469-0691.2005.01332.x PMID: 16441450
11. Ryan JL, Fan H, Glaser SL, Schichman SA, Raab-Traub N, Gulley ML. Epstein-Barr virus quantitation by real-time PCR targeting multiple gene segments: a novel approach to screen for the virus in paraffin-embedded tissue and plasma. J Mol Diagn JMD. 2004; 6: 378–385. https://doi.org/10.1016/S1525-1578(10)60535-1 PMID: 15507678
12. Tierney RJ, Kao K-Y, Nagra JK, Rickinson AB. Epstein-Barr Virus BamHI W Repeat Number Limits EBNA2/EBNA-LP Coexpression in Newly Infected B Cells and the Efficiency of B-Cell Transformation: a Rationale for the Multiple W Repeats in Wild-Type Virus Strains. J Virol. 2011; 85: 12362–12375. https://doi.org/10.1128/JVI.06059-11 PMID: 21957300
13. Jones MD, Griffin BE. Clustered repeat sequences in the genome of Epstein-Barr virus. Nucleic Acids Res. 1983; 11: 3919–3937. https://doi.org/10.1093/nar/11.12.3919 PMID: 6306567
14. Allan GJ, Rowe DT. Size and stability of the Epstein-Barr virus major internal repeat (IR-1) in Burkitt’s lymphoma and lymphoblastoid cell lines. Virology. 1989; 173: 489–498. PMID: 2556840
15. Le Q-T, Jones CD, Yau T-K, Shirazi HA, Wong PH, Thomas EN, et al. A Comparison Study of Different PCR Assays in Measuring Circulating Plasma Epstein-Barr Virus DNA Levels in Patients with Nasopharyngeal Carcinoma. Am Assoc Cancer Res. 2005; 11: 5700–5707. https://doi.org/10.1158/1078-0432.CCR-05-0468 PMID: 1615906
16. Abeynayake J, Johnson R, Libiran P, Sahoo MK, Cao H, Bowen R, et al. Commutability of the Epstein-Barr Virus WHO International Standard across Two Quantitative PCR Methods. J Clin Microbiol. 2014; 52: 3802–3804. https://doi.org/10.1128/JCM.01676-14 PMID: 25078918
17. Mukohyama J, Iwakiri D, Zen Y, Mukohara T, Minami H, Kakeji Y, et al. Evaluation of the risk of lymphomagenesis in xenografts by the PCR-based detection of EBV BamHI W region in patient cancer specimens. Oncotarget. 2016; https://doi.org/10.18632/oncotarget.10322 PMID: 27367028
18. Hadinoto V, Shapiro M, Greenough TC, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis. Blood. 2008; 111: 1420–1427. https://doi.org/10.1182/blood-2007-06-093278 PMID: 17991806
19. Ryan JL, Morgan DR, Dominguez RL, Thorne LB, Elmore SH, Mino-Kenudson M, et al. High levels of Epstein-Barr virus DNA in latently infected gastric adenocarcinoma. Lab Invest J Tech Methods Pathol. 2009; 89: 80–90. https://doi.org/10.1038/labinvest.2008.103 PMID: 1902111

20. Fafi-Kremer S, Morand P, Barranger C, Barguès G, Magro S, Bès J, et al. Evaluation of the Epstein-Barr Virus R-Gene Quantification Kit in Whole Blood with Different Extraction Methods and PCR Platforms. J Mol Diagn JMD. 2008; 10: 78–84. https://doi.org/10.2353/jmoldx.2008.070054 PMID: 18165270

21. Semenova T, Lupi J, Alain S, Perrin-Confort G, Grossi L, Dimier J, et al. Multicenter evaluation of whole-blood Epstein-Barr viral load standardization using the WHO international standard. J Clin Microbiol. 2016; 54: 1746–1750. https://doi.org/10.1128/JCM.03336-15 PMID: 27076661

22. Burd EM. Validation of Laboratory-Developed Molecular Assays for Infectious Diseases. Clin Microbiol Rev. 2010; 23: 550–576. https://doi.org/10.1128/CMR.00074-09 PMID: 20610823

23. Kimura H, Morita M, Yabuta Y, Kuzushima K, Kato K, Kojima S, et al. Quantitative Analysis of Epstein-Barr Virus Load by Using a Real-Time PCR Assay. J Clin Microbiol. 1999; 37: 132–136. PMID: 9854077

24. Tsai DE, Douglas L, Andreadis C, Vogl DT, Arnoldi S, Kotloff R, et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg. 2008; 8: 1016–1024. https://doi.org/10.1111/j.1600-6143.2008.02183.x PMID: 18312608

25. Fryer JF, Heath AB, Wilkinson DE, Minor PD, the Collaborative Study Group. A collaborative study to establish the 1st WHO International Standard for Epstein-Barr virus for nucleic acid amplification techniques. Biol J Int Assoc Biol Stand. 2016; https://doi.org/10.1016/j.biologicals.2016.04.010 PMID: 27461128

26. van der Velden WJFM, Mori T, Stevens WBC, de Haan AFJ, Stelma FF, Blijlevens NMA, et al. Reduced PTLD-related mortality in patients experiencing EBV infection following allo-SCT after the introduction of a protocol incorporating pre-emptive rituximab. Bone Marrow Transplant. 2013; 48: 1465–1471. https://doi.org/10.1038/bmt.2013.84 PMID: 23749107

27. Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, et al. Pre-emptive rituximab based on viremia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematol. 2011; 155: 377–385. https://doi.org/10.1111/j.1365-2457.2011.08855.x PMID: 21910716

28. Patriarca F, Medeot M, Isola M, Battista ML, Sperotto A, Pipan C, et al. Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis Off J Transplant Soc. 2013; 15: 259–267. https://doi.org/10.1111/tid.12061 PMID: 23405972

29. Ishii H, Ogino T, Berger C, Köchli-Schmitz N, Nagato T, Takahara M, et al. Clinical usefulness of serum EBV DNA levels of BamHI W and LMP1 for Nasal NK/T-cell lymphoma. J Med Virol. 2007; 79: 562–572. https://doi.org/10.1002/jmv.20853 PMID: 17385697

30. Peng R, Moses SC, Tan J, Kremmer E, Ling PD. The Epstein-Barr Virus EBNA-LP Protein Preferentially Coactivates EBNA2-Mediated Stimulation of Latent Membrane Proteins Expressed from the Viral Divergent Promoter. J Virol. 2005; 79: 4492–4505. https://doi.org/10.1128/JVI.79.7.4492-4505.2005 PMID: 15767449

31. Szekely L, Selivanova G, Magnusson KP, Klein G, Wiman KG. EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A. 1993; 90: 5455–5459. PMID: 8390666